Kymera Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
KYMR$138.86+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except for share and per share amounts)
| June 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $335,816 | $120,256 |
| Marketable securities (Note 4) | 329,629 | 368,488 |
| Accounts receivable | 40,000 | — |
| Contract assets | — | 947 |
| Prepaid expenses and other current assets | 22,882 | 20,577 |
| Total current assets | 728,327 | 510,268 |
| Marketable securities, non-current (Note 4) | 297,629 | 362,159 |
| Property and equipment, net (Note 6) | 48,572 | 50,457 |
| Right-of-use assets, operating leases | 46,045 | 47,407 |
| Other non-current assets | 4,675 | 1,950 |
| Restricted cash | 5,820 | 5,794 |
| Total assets | $1,131,068 | $978,035 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $5,781 | $5,989 |
| Accrued expenses (Note 8) | 27,976 | 34,867 |
| Deferred revenue | 40,000 | 13,576 |
| Operating lease liabilities | 11,766 | 11,594 |
| Finance lease liabilities | 1,900 | 1,518 |
| Other current liabilities | 117 | 223 |
| Total current liabilities | 87,540 | 67,767 |
| Non-current liabilities | ||
| Operating lease liabilities, net of current portion | 69,835 | 72,423 |
| Finance lease liabilities, net of current portion | 2,213 | 2,226 |
| Total liabilities | 159,588 | 142,416 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.0001 par value; 150,000,000 shares authorized at June 30, 2025 and December 31, 2024, 70,557,442 and 64,890,193 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 7 | 7 |
| Additional paid-in capital | 1,867,999 | 1,591,707 |
| Accumulated deficit | (896,805) | (754,610) |
| Accumulated other comprehensive loss | 279 | (1,485) |
| Total stockholders’ equity | 971,480 | 835,619 |
| Total liabilities and stockholders’ equity | $1,131,068 | $978,035 |
KYMERA THERAPEUTICS, INC
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.